MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease

Detalles Bibliográficos
Autores principales: Hegemann, Inga, Sasselli, Clelia, Valeri, Fabio, Makhro, Asya, Müller, Rouven, Bogdanova, Anna, Manz, Markus G., Gassmann, Max, Goede, Jeroen S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430229/
https://www.ncbi.nlm.nih.gov/pubmed/32885144
http://dx.doi.org/10.1097/HS9.0000000000000452
_version_ 1783571390460329984
author Hegemann, Inga
Sasselli, Clelia
Valeri, Fabio
Makhro, Asya
Müller, Rouven
Bogdanova, Anna
Manz, Markus G.
Gassmann, Max
Goede, Jeroen S.
author_facet Hegemann, Inga
Sasselli, Clelia
Valeri, Fabio
Makhro, Asya
Müller, Rouven
Bogdanova, Anna
Manz, Markus G.
Gassmann, Max
Goede, Jeroen S.
author_sort Hegemann, Inga
collection PubMed
description
format Online
Article
Text
id pubmed-7430229
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer Health
record_format MEDLINE/PubMed
spelling pubmed-74302292020-09-02 MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease Hegemann, Inga Sasselli, Clelia Valeri, Fabio Makhro, Asya Müller, Rouven Bogdanova, Anna Manz, Markus G. Gassmann, Max Goede, Jeroen S. Hemasphere Letter Wolters Kluwer Health 2020-08-11 /pmc/articles/PMC7430229/ /pubmed/32885144 http://dx.doi.org/10.1097/HS9.0000000000000452 Text en Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. http://creativecommons.org/licenses/by-nc/4.0 This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC), where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc/4.0
spellingShingle Letter
Hegemann, Inga
Sasselli, Clelia
Valeri, Fabio
Makhro, Asya
Müller, Rouven
Bogdanova, Anna
Manz, Markus G.
Gassmann, Max
Goede, Jeroen S.
MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease
title MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease
title_full MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease
title_fullStr MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease
title_full_unstemmed MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease
title_short MEMSID: Results From a Phase 2 Pilot Study on Memantine Treatment for Sickle Cell Disease
title_sort memsid: results from a phase 2 pilot study on memantine treatment for sickle cell disease
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430229/
https://www.ncbi.nlm.nih.gov/pubmed/32885144
http://dx.doi.org/10.1097/HS9.0000000000000452
work_keys_str_mv AT hegemanninga memsidresultsfromaphase2pilotstudyonmemantinetreatmentforsicklecelldisease
AT sasselliclelia memsidresultsfromaphase2pilotstudyonmemantinetreatmentforsicklecelldisease
AT valerifabio memsidresultsfromaphase2pilotstudyonmemantinetreatmentforsicklecelldisease
AT makhroasya memsidresultsfromaphase2pilotstudyonmemantinetreatmentforsicklecelldisease
AT mullerrouven memsidresultsfromaphase2pilotstudyonmemantinetreatmentforsicklecelldisease
AT bogdanovaanna memsidresultsfromaphase2pilotstudyonmemantinetreatmentforsicklecelldisease
AT manzmarkusg memsidresultsfromaphase2pilotstudyonmemantinetreatmentforsicklecelldisease
AT gassmannmax memsidresultsfromaphase2pilotstudyonmemantinetreatmentforsicklecelldisease
AT goedejeroens memsidresultsfromaphase2pilotstudyonmemantinetreatmentforsicklecelldisease

Ejemplares similares